SCHEMBL38414

SCHEMBL38414

O=C(O)c1ccc(Br)nc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HA1 P13674 3/20 0.61
P4HTM Q9NXG6 2/20 0.61
MIF P14174 1/20 0.59
GABRP O00591 1/20 0.57
GABRD O14764 1/20 0.57
GABRA1 P14867 1/20 0.57
GABRB1 P18505 1/20 0.57
GABRG2 P18507 1/20 0.57
GABRB3 P28472 1/20 0.57
GABRA5 P31644 1/20 0.57
GABRA3 P34903 1/20 0.57
GABRA2 P47869 1/20 0.57
GABRB2 P47870 1/20 0.57
GABRA4 P48169 1/20 0.57
GABRE P78334 1/20 0.57
GABRA6 Q16445 1/20 0.57
GABRG1 Q8N1C3 1/20 0.57
GABRG3 Q99928 1/20 0.57
GABRQ Q9UN88 1/20 0.57
NAPRT Q6XQN6 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29751460 1.00 P4HA1 (0.61) P4HA1P4HTMMIFGABRPGABRD
Hydrochloric Acid SCHEMBL1871783 0.98 P4HA1 (0.59) P4HA1P4HTMMIFGABRPGABRD
Nitrous Acid SCHEMBL27425985 0.92 P4HA1 (0.53) P4HA1P4HTMMIFGABRPGABRD
SCHEMBL9035328 0.92 ALDH1A1 (0.55) P4HA1P4HTMMIFGABRPGABRD
SCHEMBL5973043 0.84 RXFP1 (0.44) P4HA1P4HTMMIFGABRPGABRD
SCHEMBL3500140 0.83 HCAR3 (0.69) HCAR3
SCHEMBL2655448 0.83 CPT1B (0.45) P4HA1P4HTMMIFGABRPGABRD
SCHEMBL31078250 0.83 CPT1B (0.45) P4HA1P4HTMMIFGABRPGABRD
SCHEMBL7312742 0.82 P4HA1 (0.40) P4HA1P4HTMMIFGABRPGABRD
SCHEMBL15773930 0.80 NAPRT (0.41) P4HA1P4HTMMIFGABRPGABRD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 895 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119431432-A Andrographolide diester derivative, preparation method and application 西北农林科技大学 2025-02-14 CN claimed
CN-115433122-B Preparation method of 6-fluoro nicotinic acid 大连双硼医药化工有限公司 2024-01-30 CN claimed
CN-116987064-B Preparation method and application of pyrimidine bisnicotinamide derivative 宁夏佰斯特医药化工有限公司 2024-01-26 CN claimed
CN-116987064-A Preparation method and application of pyrimidine bisnicotinamide derivative 宁夏佰斯特医药化工有限公司 2023-11-03 CN claimed
CN-115433122-A Preparation method of 6-fluoronicotinic acid 大连双硼医药化工有限公司 2022-12-06 CN claimed
EP-4053117-A1 ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS Achillion Pharmaceuticals, Inc. (US) 2022-09-07 EP claimed
WO-2022078279-A1 ANTIBODY-DRUG CONJUGATE AND USE THEREOF 昆山新蕴达生物科技有限公司 2022-04-21 WO claimed
CN-113046734-A Bivalent palladium complex solution and preparation method and application thereof 上海天承化学有限公司 2021-06-29 CN claimed
CN-110317204-A Pyrazolopyrimidinonefor derivative and its preparation method and application 安徽农业大学 2019-10-11 CN claimed
CN-108727295-A A kind of 2- (3- aminophenyls)-benzothiazole derivant and its preparation method and application 济南大学 2018-11-02 CN claimed
JP-9176122-A None JP disclosed
EP-4741392-A1 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF Shenzhen TargetRx Co., Ltd. (CN) 2026-05-13 EP disclosed
CN-116323601-B 2- (3-Pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl) -acetamide derivatives as transforming growth factor-beta receptor I/ALK5 inhibitors 阿戈麦布西班牙股份有限公司 2026-05-12 CN disclosed
US-12612368-B2 Cancer treatments targeting cancer stem cells REMEDY PLAN, INC. (US) 2026-04-28 US disclosed
EP-4720060-A1 PRMT5 INHIBITORS Ryvu Therapeutics S.A. (PL) 2026-04-08 EP disclosed
WO-1993006118-A1 ANTIBACTERIAL, ANTIMYCOPLASMAL COMPOUNDS RELATED TO MUPIROCIN SMITHKLINE BEECHAM PLC (GB) 1993-04-01 WO disclosed
EP-0244728-B1 USE OF HETEROARYLETHYL AMINES TO STIMULATE ANIMAL GROWTH, HETEROARYLETHYL AMINES AND PROCESS FOR THEIR PREPARATION BAYER AG (DE) 1992-11-11 EP disclosed
EP-0506729-A1 PHARMACEUTICALLY ACTIVE OXAZOLE COMPOUNDS Beecham Group p.l.c. (GB) 1992-10-07 EP disclosed
WO-1991009856-A1 PHARMACEUTICALLY ACTIVE OXAZOLE COMPOUNDS BEECHAM GROUP PLC (GB) 1991-07-11 WO disclosed
US-4112102-A Halopyridyl derivatives of m-aminotetramisole as anthelmintics PFIZER INC. (US) 1978-09-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612368-B2 Cancer treatments targeting cancer stem cells MALT1, BCOR, MCL1 P4HA1 310/4885P4HTM 1194/4885MIF 3233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.